Stratipath breast is demonstrating considerable agreement with established gene expression test
The findings showed that the Stratipath Breast analysis identified 49.6% of the clinically intermediate tumors as low risk and 50.4% as high risk. The Prosigna assay classified 32.5%, 47.0% and 20.5% tumors as low, intermediate and high risk, respectively. Among Prosigna intermediate-risk tumors, 47.3% were stratified as Stratipath low risk and 52.7% as high risk. In addition, 89.7% of Stratipath low-risk cases were classified as Prosigna low/intermediate risk. The overall agreement between the two tests for low-risk and high-risk groups (N = 124) was 71.0%, with a Cohen’s kappa of 0.42. For both risk profiling tests, grade and Ki67 differed significantly between risk groups.
Unilabs is implementing Stratipath Breast for enhanced breast cancer diagnostics at Capio S:t Göran’s Hospital
Capio St Göran’s Hospital is one of the largest breast cancer clinics in Sweden treating more than 600 breast cancer patients annually. With this new collaboration, Unilabs will use Stratipath Breast on a selected group of these patients.
